• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

UK Government (DFID) Renews Multi-Year Support of DNDi to Improve Medicines for the Most Neglected

Geneva, Switzerland — 15 May 2009
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

5-year, GBP 18 Million Grant Supports DNDi’s Proven Drug Development Model
The UK’s Department of International Development (DFID) renewed its support of the Drugs for Neglected Diseases initiative (DNDi) with a GBP18 million (EUR 20 million) grant.  The funds will be used to research and develop new, improved treatments for a group of deadly neglected diseases, for which current treatments are inadequate in that they are often toxic, prohibitively expensive, or difficult to be administered, particularly in resource-poor settings.

DFID, the first major government donor of DNDi with a three-year grant awarded in 2005, will disburse the new funds over the next five years. The grant will cover a broad spectrum of drug research, development, and access activities undertaken by DNDi and its partners to address the imbalance between investment in medical research and global disease burden, often referred to as the 10-90 gap.

“NECT represents a breakthrough in the current treatment of sleeping sickness; and efforts to progress fexinidazole could lead to a simple and more effective oral treatment,” commented Ivan Lewis, UK International Development Minister. “That is why it is important we continue to invest in research like DNDi’s that will discover new treatments that are affordable, effective and that could ultimately save millions of lives.”
With a robust portfolio including a balanced mix of early-stage discovery and late-stage clinical development projects, DNDi is well on its way to reaching its objective to deliver six to eight new, improved, and field-relevant treatments by 2014, with two new malaria treatments already available in Africa and Latin America. This past month, Nifurtimox-Eflornithine Combination Therapy (NECT), an improved treatment against sleeping sickness, was included onto the Essential Medicines List (EML) of the World Health Organization (WHO), thus paving the way for NECT – only the 2nd new treatment option for sleeping sickness in the last 50 years.
“We congratulate and thank DFID for its continued leadership in dedicating thought, action, and money to addressing the plight of the most neglected suffering around the world. This funding will enable us to make available the safe, effective, practical-to-use, and affordable treatments so desperately needed by patients,” remarked Dr. Bernard Pécoul, Executive Director of DNDi. “We urge other governments to join the fight against these devastating diseases as, together, this is a battle we can win.”

***

About neglected diseases
Neglected tropical diseases cause significant morbidity and mortality worldwide, and exact a worldwide cost that is greater than road traffic accidents or tuberculosis (1).  For some of these neglected tropical diseases (like sleeping sickness, leishmaniasis, and Chagas disease), no adequate tools exist to prevent, diagnose or treat these fatal conditions, due to a combination of market and public policy failures.
• In 2007, less than 5% of USD 2.5 billion in total funding for neglected diseases R&D went to these deadly diseases (2).
• Between the period from 1975 to 2004, only 21 new drugs (out of 1,556 developed in total) were developed for tropical diseases and tuberculosis: this is 1.3% of new drugs developed, even though these diseases account for 12% of the global disease burden (3).
• At the end of 2004, 75% of active drug development projects for neglected tropical diseases were conducted by PDPs, with eight to nine new drugs expected in the market by 2010 (4). To date, PDPs have made available three new treatments to patients.

About about NECT inclusion onto the Essential Medicines List of the World Health Organization:
Available at: http://www.who.int/neglected_diseases/disease_management/drug_combination/en/index.html

About DNDi
The Drugs for Neglected Diseases initiative (DNDi) is an independent, not-for-profit product development partnership working to research and develop new and improved treatments for neglected diseases such as leishmaniasis, human African trypanosomiasis (HAT), Chagas disease, and malaria. With the objective to address unmet patient needs for these diseases, DNDi has developed the largest ever R&D portfolio for the kinetoplastid diseases and has already made available two new antimalarial treatments.  In December 2008, DNDi, Epicentre, and MSF released promising Phase III clinical study results of NECT (nifurtimox-eflornithine combination therapy), which show NECT is a safe, effective treatment for the advanced stage of HAT.

DNDi was founded in 2003 by the humanitarian organisation Médecins sans Frontières/Doctors Without Borders (MSF) along with 5 research institutions: Institut Pasteur, Kenya Medical Research Institute (KEMRI), Indian Council of Medical Research (ICMR), the Foundation Oswaldo Cruz in Brazil, and the Ministry of Health in Malaysia, and. The special Programme for Research and Training in Tropical Diseases (TDR) acts as a permanent observer to the initiative.

Even with the recent funding recommitments by DFID and MSF, DNDi needs an additional EUR 160 million in funding in order to achieve its objectives of building a robust pipeline and delivering six to eight new treatments by 2014. To date, DNDi has secured EUR 114 million from public and private donors, with a sustained contribution from MSF. Significant funding has come from public donors including:  the European Union, France, Germany, the Netherlands, Spain, Switzerland, the United Kingdom, and the United States of America.

DNDi has a number of project partners in the UK who are involved at various projects throughout the drug development spectrum; these partners include London School of Hygiene & Tropical Medicine, Aptuit, BioDynamics, Covance, Imperial College, London School of Pharmacy, Oxford University, University of Dundee, and University of Liverpool

(1) Hotez et al. N Engl J Med. 2007. 357:10.
(2) The World Can’t Wait: More Funding Needed for Research on Neglected Infectious Diseases. Washington, DC: Families USA: 2008.
(3) Chirac P, Torreele E. Lancet. 2006 May 12; 1560-1561.
(4) Moran et al. The New Landscape of Neglected Disease Drug Development. London, UK: Pharmaceutical R&D Policy Project, London School of Economics. 2005

Media Contacts

DNDi
Sadia Kaenzig, DNDi Geneva, +41 (0)79 819 99 71
skaenzig@dndi.org

Ann-Marie Sevcsik, DNDi Geneva, +41 (0)79 814 9147 or +1 646-258-8131
amsevcsik@dndi.org

Michelle French, DNDi North America, (212) 298-3743 or +1-646-552-4600
mfrench@dndi.org

Funding

Read, watch, share

Loading...
Young man sitting in hospital setting
News
25 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

Child receiving treatment
News
20 Jan 2023

DNDi’s 20th year of bringing the best science for the most neglected

Child affected by dengue and her mother at their home in Bangkok, Thailand.
Stories
16 Dec 2022

2022: Six advances in neglected disease research to remember

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

Healthcare workers looking into microscopes
Press releases
30 Nov 2022

Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa

Journalists talking with healthcare workers
News
23 Nov 2022

DNDi media workshops – bringing together reporters and researchers to cover neglected disease research

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo